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Abstract
Background: Areas endemic for Plasmodium falciparum, hepatitis B virus (HBV) and hepatitis C virus (HCV) overlap in many
parts of sub-Saharan Africa. HBV and HCV infections develop in the liver, where takes place the first development stage of P.
falciparum before its further spread in blood. The complex mechanisms involved in the development of hepatitis may
potentially influence the development of the liver stage of malaria parasites. Understanding the molecular mechanisms of
these interactions could provide new pathophysiological insights for treatment strategies in Malaria.
Methodology: We studied a cohort of 319 individuals living in a village where the three infections are prevalent. The
patients were initially given a curative antimalarial treatment and were then monitored for the emergence of asexual P.
falciparum forms in blood, fortnightly for one year, by microscopy and polymerase chain reaction.
Principal Findings: At inclusion, 65 (20.4%) subjects had detectable malaria parasites in blood, 36 (11.3%) were HBV chronic
carriers, and 61 (18.9%) were HCV chronic carriers. During follow-up, asexual P. falciparum forms were detected in the blood
of 203 patients. The median time to P. falciparum emergence in blood was respectively 140 and 120 days in HBV- and HBV+
individuals, and 135 and 224 days in HCV- and HCV+ individuals. HCV carriage was associated with delayed emergence of
asexual P. falciparum forms in blood relative to patients without HCV infection.
Conclusions: This pilot study represents first tentative evidence of a potential epidemiological interaction between HBV,
HCV and P. falciparum infections. Age is an important confounding factor in this setting however multivariate analysis
points to an interaction between P. falciparum and HCV at the hepatic level with a slower emergence of P. falciparum in HCV
chronic carriers. More in depth analysis are necessary to unravel the basis of hepatic interactions between these two
pathogens, which could help in identifying new therapeutic approaches against malaria.
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Introduction
Areas where malaria, hepatitis B (HBV) and hepatitis C (HCV)
are prevalent frequently overlap in sub-Saharan Africa [1,2,3].
However, studies of Plasmodium and hepatitis virus coinfection are
rare [4,5,6,7]despitethefactthat liver-stagemalariaparasites,HBV
and HCV viruses all develop in hepatocytes and may thus interact.
The simultaneous presence of both pathogens in the liver could lead
to two ‘‘opposing’’ phenomena: reduced HLA class I expression on
infected hepatocytes that would protect the developing hepatic
malaria parasite from destruction [8], or inhibition of the
development of the hepatic malaria parasite through the induction
of non-specific inflammatory factors. The fact that different
molecules such as CD81 [9], Scavenger Receptor B1 [10] are
implicated in some of the early invasive steps of hepatocytes by
hepatitis virus and P. falciparum, further makes functional investiga-
tion of co-infected hosts highly interesting.
We therefore conducted a prospective longitudinal study
designed to determine whether HBV or HCV infection interferes
with pre-erythrocytic development of P. falciparum. This was done
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blood after a radical cure, such a delay denoting an alteration in
hepatocyte receptivity to the parasite [11,12]. We studied
individuals living in Dienga, a village located in an area of
south-eastern Gabon where malaria is hyperendemic and where
preliminary studies have shown high HBV and HCV seroprev-
alence rates ([13] and Makuwa et al, unpublished data).
Methods
Study area
The study took place from February 2003 to March 2004 in
Dienga, a village located in Ogooue ´ Lolo province (south-eastern
Gabon, near the Congo border), approximately 200 km (a 3-hour
drive) from Franceville. The population of Dienga belongs to the
Banzabi ethnic group [14]. In 1994 a fully equipped field base was
established in this village of nearly 2500 inhabitants, and three
permanent CIRMF team members ensure full-time monitoring of
study cohorts [15]. Malaria is highly endemic in this rain forest
area, with seasonal peaks of transmission coinciding with the rains,
from February to June and from September to December. The
main malaria species is P. falciparum (.80%) and transmission is
predominantly due to Anopheles gambiae, with an estimated 100
infective bites per person per year [16].
Patients
Individuals aged 13–85 years residing permanently in Dienga
were the focus of this study. All volunteers were interviewed in
French or the local language and received a physical examination.
Written informed consent was obtained from each volunteer or
tutor before enrolment. The exclusion criteria were i) known
severe illness other than malaria or hepatitis, ii) first quarter of
pregnancy, iii) likely problems with follow-up; and iv) known
hypersensitivity to sulfadoxine-pyrimethamine (SP) and/or arte-
sunate (AS). A total of 319 individuals were enrolled, and each was
attributed a unique number for this study.
Study design
Baseline (day 0) blood samples were collected from each
volunteer, and 2 to 4 aliquots of serum, ethylenediaminetetraacetic
acid (EDTA)-plasma and buffy coat were frozen at 220uC and/or
in liquid nitrogen for transportation to CIRMF headquarters for
biochemical, parasitological and virological analyses. A thick blood
smear was prepared for direct examination and three drops of
blood were deposited on calibrated pre-punched paper disks
(Serobuvard, LDA
22H, Zoopole, Ploufragan, France) [17] for
molecular studies. After 4 h at room temperature, the dried blood
spots (DBS) were placed in envelopes, transported to CIRMF, and
stored in an air-conditioned room until use. In keeping with WHO
recommendations [18], all the volunteers were given oral
artemisinin-based combination therapy (ACT) as follows: one
dose of 25 mg/kg sulfadoxine plus 1.25 mg/kg pyrimethamine on
day 0, and three doses of AS 4 mg/kg (ArsumaxH, Sanofi, France),
on days 0, 1 and 2 [19]. All the subjects were directly observed for
at least 30 min following the intakes and were given a new dose if
vomiting occurred.
Each volunteer was given an individual appointment calendar
mentioning the date of inclusion and the dates of planned
fortnightly follow-up visits to the CIRMF field base. Volunteers
who missed an appointment were visited at home by a team
member to prepare a blood smear and DBS. Volunteers who were
absent were actively sought in order to avoid missing data. Each
volunteer was given an individual card summarizing his or her
personal information and all parasitological results. Patients found
to be parasitemic either during the follow-up period or on any day
after initial treatment were interviewed and physically examined
before being treated with SP if asymptomatic, or with quinine
(QuinimaxH tablets for seven days) if symptomatic (fever $37.5uC
and parasitemia .5000 p/ml of blood and no apparent other
cause of fever [20]). Patients were excluded from the study once
they had been treated. The entire population of Dienga was
invited to see a doctor at the CIRMF base at any time during the
study period and, when necessary, received medications and/or
laboratory tests free of charge. Moreover, in 2005, HBV
vaccination was proposed for every child under 5 years of age in
Dienga (about 200 children were vaccinated). Individuals with
clinical or biological signs of hepatitis were followed closely. The
project was approved by the Gabonese Ministry of Public Health,
the governor of the province, the local prefect, and the village
authorities. Written informed consent was obtained from all
participants prior enrolment. All clinical investigations have been
conducted according to the international ethical standards.
Laboratory testing
Diagnosis of HBV and HCV infections and transaminase
assays. They were performed at CIRMF, on samples taken on
day 0. Plasma samples were used for HBV and HCV testing. Anti-
HCV antibodies were detected with a third-generation enzyme
immunoassay (Monolisa anti-HCV Plus version 2, Bio-Rad,
Marnes-La-Coquette, France). Positive and doubtful samples
were retested with a third-generation recombinant strip
immunoblot assay (RIBA, Chiron Corporation, Emeryville, CA).
Samples positive in both tests were tested for HCV RNA by using
qualitative reverse transcriptase polymerase chain reaction (PCR)
amplification of the 59 non coding region, as previously described
[13,21,22]. All HCV RNA-positive individuals were considered to
be HCV chronic carriers. Total anti-HBc antibodies and HBsAg
were detected with enzyme immunoassays (Monolisa anti-HBc
Plus and Monolisa Ag HBs Plus, Bio-Rad, Marnes-La-Coquette,
France). Subjects positive in both tests were considered to be HBV
chronic carriers.
Serum concentrations of glutamic oxalacetic and glutamic
pyruvic transaminase (SGOT and SGPT) were determined with a
Hitachi 902 analyzer (Roche Diagnostics, Mannheim, Germany)
and aminotransferase activities were determined with a kinetic
method (Enzyline GOT and Enzyline GPT respectively, Biomer-
ieux, Marcy l’Etoile, France). SGOT and SGPT levels were
considered abnormal if above 40 IU/L.
Malaria. It was diagnosed by microscopic examination of
thick blood smears stained with Giemsa, and by PCR.
Microscopic examinations were performed at CIRMF by three
pairs of readers, each consisting of one senior microscopist and one
laboratory technician. The pairs of readers were alternated on a
weekly basis, following a preset schedule. Positive smears were
examined against 200 white blood cells, and parasite density was
calculated as the number of parasites per microliter of blood,
based on a putative mean white blood cell count of 8000/mL.
Samples were only considered negative after examining the entire
thick smear. A single P. falciparum parasite was detected in some
samples, giving an estimated limit of detectable parasite density of
0.1 p/mL, assuming that about 10 mL of blood was used to prepare
a thick smear. Each positive slide was systematically confirmed by
all three senior microscopists. Routine quality controls were
implemented, whereby 10% of randomly selected smears were re-
examined, blindly to the initial result, by one of the three senior
microscopists, on a rotating schedule (never the senior microsco-
pist who initially examined the slide). Individuals with positive
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excluded from the study.
Microscopy-negative samples were submitted to PCR targeting
the gene encoding P. falciparum SSUrRNA, as previously described
[23]. PCR could not distinguish between asexual and sexual
parasites.
DNA extraction. Template DNA was extracted from DBS by
using Chelex100, as described by Plowe [24].
DNA amplification. Each DNA sample (2.5 mL) was
amplified in a Perkin Elmer thermal cycler. Amplification was
carried out in a final volume of 25 mL containing 1xPCR buffer (as
supplied by the manufacturer: 200 mM Tris, 100 mM KCl,
100 mM (NH4)2SO4, 20 mM MgSO4, 1% Triton x100, 1 mg/
mL bovine serum albumin), 200 mM each dNTP (dATP, dCTP,
dGTP and dTTP), 1 mM of each primer and 1 unit of Taq DNA
polymerase (Invitrogen, Cergy Pontoise, France). First- and
second-round amplifications were performed as reported by
Snounou et al [23]. After amplification, 15 mL of each nested
PCR product was analysed by electrophoresis on 1.5% agarose gel
and visualized by UV transillumination after staining with GelRed
(Interchim, Montluc ¸on, France). A specific DNA band of 205 base
pairs signals P. falciparum infection.
Assessmentofpotentialantimalarialself-medication. The
patients were asked not to use antimalarial drugs during the follow-up
period. To evaluate possible self-medication, the patients were
individually interviewed using a questionnaire. The use of
antimalarial drugs was also evaluated with the Saker-Solomons test
for 4-aminoquinoleine metabolites in urine samples from 53
randomly chosen subjects [25].
Assessment of the time to P. falciparum emergence in
blood. The time to P. falciparum emergence was defined as the
period (in days) between the end of the initial potentially
curative treatment (on D0) and the detection of P. falciparum
blood stages, irrespective of clinical status. Blood stages of P.
falciparum were considered to have emerged at the midpoint
between the last negative and the first positive diagnostic test
(microscopy or PCR) after initial curative treatment. Follow-up
was terminated if patients had at least two/three or more
consecutive missing data points (corresponding to an absence of
at least one month) and if antimalarial self-medication was
detected by interview or metabolite assay. These patients were
considered as being uninfected until the day before follow-up was
terminated.
Statistical analysis
All data were entered and verified with Excel or Access software
(Microsoft). Statistical analyses were performed with Epi-Info 6.0
(CDC, Atlanta, GA) and Statview 5.0 (SAS Institute Inc., Cary,
NC). Descriptive analysis used means 6 standard deviation (SD) for
quantitative variables and proportions (%) for qualitative variables.
Means were compared using Student’s t test and proportions were
compared using the chi-square test. The chi-square test for trends
was used to estimate prevalence trends across the different age
groups. Survival rates were estimated with the Kaplan-Meier
method and compared using the log-rank test, according to sex, age
and hepatitis virus serostatus. Cox multivariate analysis included all
variables with univariate P values of ,0.25, and a stepwise
backwards procedure was used until the final model was obtained.
The level of significance was set at 5% for all analyses.
Results
A total of 319 individuals (136 males and 183 females, sex ratio
0.74) aged from 13 to 85 years (mean 6 SD =38.2618.6 years)
were included in this study (Table 1). The predominance of
females (57.4% versus 42.6%; P=0.0004) reflected the sex
distribution of the entire population of Dienga at the time of the
study (data not shown).
Hepatitis virus serostatus (Table 1)
Of the 319 subjects, 36 (11.3%; age 15–57 years, sex ratio 1.57)
were HBV chronic carriers and 61 (19.1%; age 13–85 years, sex
ratio 0.65) were HCV chronic carriers. Two women (36 and 43
years) carried both viruses. These two patients were included in
both the HBV and HCV carrier groups and were not analyzed as
a distinct group. Transaminase levels were elevated in 32
individuals (10.1%), of whom seven were HBV carriers (19.5%
of this group) and 13 were HCV carriers (21.7% of this group).
The remaining 12 patients were HBV- and HCV-negative.
Malaria status (Figure 1)
Sixty-five cases of P. falciparum infection (20.4% of the cohort)
were diagnosed before treatment, 23 (7.2%) by microscopy and 42
(13.2%) by PCR (Figure 1).
Two weeks after initial treatment, 278 (87.14%) patients were
examined and all had negative thick blood smears, while 25
patients (8.99%) had submicroscopic infection (SMI) [26]. Among
Table 1. Characteristics of the whole cohort and of participants according to HBV and HCV serostatus.
Characteristics Whole cohort HBV chronic carriers HBV neg HVC chronic carriers HCV neg
n (%) 319 (100) 36 (11.3) 283 (88.7) 61 (19.1) 258 (80.9)
male (%) 136 (42.6)* 22 (61.1) 114 (40.3) 24 (39.3) 112 (43.4)
female (%) 183 (57.4) 14 (39.9) 169 (59.7) 37 (61.7) 146 (56.4)
age range 13–85 15–57 13–85 13–85 15–78
mean age (+/2SD) 38.2 (+/218.6) 27.0 (+/29.9) 39.6 (+/218.9) 57.7 (+/214.3) 33.6 (+/216.3)
range GOT
1 6–609 7–249 6–609 9–154 6–609
mean GOT (+/2SD) 26 (+/240) 36 (+/243) 25 (+/240) 31(+/225) 25 (+/243)
range GPT
2 5–1473 8–289 5–1473 8–163 5–1473
mean GPT (+/2SD) 25 (+/284) 31 (+/250) 25 (+/288) 26 (+/223) 25 (+/293)
abnormal levels of transaminases
3 n (%) 32 (10.1) 7 (19.5) 25 (8.9) 13 (21.7) 19 (7.4)
P=0.0004
£ two persons not tested.
doi:10.1371/journal.pone.0016034.t001
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genetically identical P. falciparum strains before and after treatment
and thus were considered to have treatment failure.
During the one-year follow-up period, 203 cases of P. falciparum
infection (63.6%) were diagnosed, 108 by microscopy and 95 by
PCR (Figure 1).
Among the 203 subjects who were positive by direct
examination or PCR after initial treatment, 25 were HBV carriers
(69.4% of the 36 HBV carriers). Parasite density ranged from 0.4
to 4800 p/mL and all these subjects were asymptomatic (Figure 2).
Twenty-eight of the 203 patients were HCV carriers (45.9% of the
61 HCV carriers). Parasite density ranged from 0.1 to 6000 p/mL
and one patient was symptomatic (Figure 2).
Self-treatment was detected by 4-aminoquinoline metabolite
assay in 11.3% of the tested individuals (data not shown).
Age distribution (Figure 3)
Most HBV carriers were younger than 30 years and only one
was older than 45 years. The HBV-Ag seroprevalence rate fell
markedly with age (P,0.0001) and HBV carriers were signifi-
cantly younger than HBV-Ag negative subjects (27.069.9 versus
39.6618.9 y; P=0.0001). By contrast, the HCV seroprevalence
rate increased markedly with age (P,10
25) and HCV carriers
were significantly older than HCV-negative subjects (57.7614.3
versus 33.6616.3 years; P,10
25).
The 65 subjects with microscopic or submicroscopic P.
falciparum infection before treatment were significantly younger
than the other subjects (31.4616.4 years versus 39.9618.7 years;
P=0.001). Similarly, the 203 subjects with post-treatment P.
falciparum infection were significantly younger than the other
subjects (35.0616.5 versus 43.8620.6 years; P,0.0001). There
was no significant age difference between the subjects diagnosed
with P. falciparum infection before initial treatment and during post-
treatment follow-up (31.4616.4 versus 35.0616.5 years; P=0.35).
The 25 P. falciparum/HBV-coinfected subjects were younger
than the other 11 HBV-infected subjects, but the difference was
not statistically significant (25.668.8 versus 30.3612.0 years;
P,0.2). In contrast, the 28 P. falciparum/HCV-coinfected subjects
Figure 1. Schematic representation of the study. The flow chart represents the total number of patients enrolled, and analyzed, and the status
of all patients at one-year follow-up.
doi:10.1371/journal.pone.0016034.g001
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subjects (52.7611.3 versus 62.0615.4 years; P=0.002).
Time to P. falciparum emergence
Blood forms of P. falciparum emerged a median of 135 days after
initial treatment. This time did not differ by gender (univariate
analysis, P=0.2; data not shown) but was significantly related to
age: subjects under 36 years (the median age) were infected more
rapidly than older subjects (P,0.0035; Fig. 4A).
The median time to P. falciparum emergence was shorter among
HBV-positive patients (120 d) than among HBV-negative patients
(140 d), although the difference was not statistically significant
(P=0.1). In contrast, the median time to P. falciparum emergence
was significantly longer (224 d) in HCV-positive patients than in
HCV-negative patients (135 d; P=0.01) (Figure 4B). The median
time to parasite emergence was also significantly longer among
subjects with stated or proven self-medication than among other
subjects (247 versus 117 days; P,0.0001).
Multivariate analysis
HCV status, age and self-medication were significantly
associated with the time to P. falciparum emergence in univariate
analysis and were therefore included in the Cox proportional
hazards model. P. falciparum emergence was mainly retarded by
self-medication (P,0.0001) and, to a lesser extent, by HCV
coinfection (P=0.0669), while age was clearly identified as a
confounding factor (Table 2).
Discussion
This study was designed to provide first epidemiological
evidence of a possible interaction at the hepatic level between P.
falciparum and hepatitis viruses. The success of this study was
largely due to the fact that the population of Dienga has been
involved in medical studies for more than 20 years and
participated actively.
The prevalence of HBV infection was 11.3%, but it should be
noted that children under 13 years of age, who usually have the
highest prevalence, were not included [27]. The HBV-Ag
seroprevalence fell markedly with age, in keeping with the results
of pioneering surveys of several rural areas of Gabon [28,29]. The
HCV seroprevalence was 18.9%, confirming the strong HCV
endemicity reported in this equatorial region [29,30,31]. The
HCV seroprevalence increased gradually with age, in accordance
with the markedly different age distribution of HCV and HBV
infection [30]. This different age distribution may explain the low
prevalence of HBV/HCV coinfection in our study (only two
cases).
During the one-year follow-up period after curative antima-
larial treatment, 203 cases of P. falciparum infection were
diagnosed, representing 63.6% of the cohort. Among these,
46.8% of infected individuals were SMI detected by PCR,
indicating that microscopic examination is a poor indicator
of P. falciparum infection [32,33,34]. However, the detection of
SMI may have been underestimated since the PCR targeting
the stevor gene has been recently reported to be more sensitive
than the one using the SSUrRNA gene [35]. Parasitological
surveillance tests were performed fortnightly in this large study
(319 subjects), rather than weekly in previous studies investigating
the re-emergence of P. falciparum after radical antimalarial
therapy, but these studies usually involved shorter follow-up
and/or smaller cohorts [36,37,38,39]. The median time to P.
falciparum emergence was 135 days in our study, compared to 115
days in a study of Dienga schoolchildren [36] but it should be
noted that children are more susceptible to infection than adults
[40].
HCV carrier status but not HBV carrier status was significantly
associated with slower emergence of malaria parasites in univariate
analysis, along with older age and self-medication. The relation
with HCV carrier status was confirmed in multivariate analysis,
although the P value was just above the threshold of significance.
As age is a confounding factor, the influence of HCV infection on
the natural course of P. falciparum malaria would be best examined
in a case-control study, as in a previous study of HBV coinfection
in the Gambia [41]. In this case-control study, Thursz et al.
showed that HBV virus carriage was significantly increased
amongst cases of severe malaria compared to matched controls.
Barcus et al.[4] found similar results in Vietnamese patients. It was
further postulated that this could be due to reduced HLA class I
expression at the surface of hepatocytes that would then lead to a
reduced destruction of intra-hepatic parasites by MHC-restricted
cytotoxic mechanisms, which are known to play an important role
in the control of malaria liver stages. Without discarding any
subversion of the immune system by HCV [8], we can propose
that the ‘‘protective’’ effect of HCV carriage may also be a
consequence of non-specific mechanisms/mediators such as
MHC-independent cytotoxic mechanisms [42,43]. Furthermore,
a number of non-specific inflammatory factors are known to be
capable of inhibiting the development of Plasmodium in the
Figure 2. Parasite density distribution according to hepatitis
virus serostatus. Parasite density distribution in the 203 patients in
whom P. falciparum blood forms emerged after the last day of initial
curative treatment, according to HBV serostatus (m, 25 positive; , 178
negative) and HCV serostatus (¤, 28 positive; , 175 negative). The
median parasite density in the 203 subjects (160 p/mL) is indicated by a
horizontal dashed line. The dotted line at 5000 p/mL corresponds to the
threshold of clinical malaria.
doi:10.1371/journal.pone.0016034.g002
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phase proteins in general (reviewed in [44,45]).
All the above non-specific factors are observed during a viral
infection [46], as the infected cells secrete cytokines and
chemokines that lead to the recruitment and activation of
inflammatory cells to the infected tissue. This is the case for NK
cells, and possibly IFN-c-secreting TNK lymphocytes. Subse-
quently, lymphocyte populations also migrate to the liver, and in
addition to their cytotoxic activity directed against infected cell,
they release IFN-c and TNF-a. The role of these two cytokines is
critical for the recruitment and activation of macrophages, NK
cells and T lymphocytes, which can in turn produce cytokines and
monokines. This inhibitory effect of the non-specific effectors on
intra-hepatic Plasmodium parasites is not surprising, such ‘‘cross-
pathogen’’ defense mechanisms have been described in transgenic
mouse models developed by the group of Chisari [5,47]. Finally, it
has been shown that different host molecules such as the
tetraspanin CD81 [9] and the Scavenger Receptor B1 [10], were
not only implicated in certain key steps of the internalization of the
virus but also of P. falciparum in hepatocytes as well. It would be
indeed astonishing if there were no interactions at play during a
combined Plasmodium/hepatitis infection. Differences in HBV and
HCV chronic infections need to be further studied to understand
the specific mechanisms in play. In vitro studies are underway to
unravel the cellular and molecular basis of this interaction between
HCV and P. falciparum.
Figure 3. Age distribution according to infection status. * P#0.0001. # P,10
25. $ P=0.001. £ P,0.002. NS, not significant.
doi:10.1371/journal.pone.0016034.g003
Figure 4. Kaplan-Meier Survival Curves for the Patients According to (A) Age or (B) Hepatitis C Virus serostatus. (A) in blue fraction of
patients #36 years old free of infection, in red patients $36 years old free of infection. (B) in blue fraction of patient HCV negatives free of infection,
in red fraction of patient HCV positive free of infection.
doi:10.1371/journal.pone.0016034.g004
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